High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome
High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome
复制标题
DOI：
10.1016/j.leukres.2014.04.015
复制
发表时间：
2014-08-01
影响因子：
2.7
通讯作者：
Nomdedeu, Benet
中科院分区：
文献类型：
--
作者：
Calvo, Xavier;Nomdedeu, Meritxell;Nomdedeu, Benet
在90例原发性骨髓增生异常综合征（MDS）患者中评估了DNA甲基化和羟甲基化对预后的影响。从诊断时获得的骨髓样品中分离DNA，并通过ELISA测定总体甲基化和羟甲基化。甲基化DNA百分比高于2.73%的患者的总生存期短于甲基化DNA水平较低的患者（p = 0.018），并且在无白血病生存期方面呈现负趋势（p = 0.084），在单变量和多变量分析中删失9例接受疾病改善治疗的患者后具有统计学显著性。类似地，由IPSS、WPSS和IPSS-R定义的低风险MDS患者，总DNA中5-mC百分比高于2.73%，总生存期较短（p = 0.032; p = 0.023; p = 0.031）。未获得对总体或无白血病生存期具有统计学显著性的5-羟甲基胞嘧啶百分比的截止值。这项研究表明，整体DNA甲基化预测骨髓增生异常综合征的总生存率。(C)2014爱思唯尔有限公司版权所有。
The prognostic impact of global DNA methylation and hydroxymethylation was assessed in 90 patients with de novo myelodysplastic syndrome (MDS). DNA was isolated from bone marrow samples obtained at diagnosis and global methylation and hydroxymethylation were determined by ELISA. Patients with a percentage of methylated DNA above 2.73% had a shorter overall survival than those with lower levels (p = 0.018) and presented a negative trend in terms of leukemia-free survival (p = 0.084), that was statistically significant after censoring 9 patients that received disease-modifying treatments both in univariate and multivariate analyses. Similarly, the low-risk MDS patients defined by the IPSS, WPSS and IPSS-R with 5-mC percentage in total DNA above 2.73% had a shorter overall survival (p = 0.032; p = 0.023; p = 0.031). No cut-off value for the 5-hydroxymethylcytosine percentage with statistical significance for overall or leukemia-free survival was obtained. This study suggests that global DNA methylation predicts overall survival in myelodysplastic syndromes. (C) 2014 Elsevier Ltd. All rights reserved.